Sai Parenteral’s IPO opened with weak demand, subscribing just 4% on day one amid no grey market premium. While retail and NII interest remained low, institutional investors stayed away. Despite strong growth and expansion plans, valuations appear expensive, prompting cautious investor sentiment.
